Zomedica, Boehringer team up on point-of-care PPID testing

Zomedica and Boehringer Ingelheim Animal Health USA have announced a strategic collaboration aimed at expanding point-of-care testing for pituitary pars intermedia dysfunction, or PPID, in horses, using Zomedica’s TRUFORMA platform. Under the arrangement, veterinarians in participating practices will be able to run rapid in-clinic endocrine testing with TRUFORMA’s equine ACTH and insulin assays, while Boehringer Ingelheim will reimburse diagnostic testing as part of the program, according to the companies’ announcement. The move links a diagnostics platform with a major equine therapeutics player that already has a strong presence in PPID management. (pharmiweb.com)

Why it matters: For equine veterinarians, the collaboration could reduce one of the biggest practical barriers in PPID workups: turnaround time. Independent reporting on TRUFORMA’s equine ACTH assay found overall good agreement with a reference chemiluminescent immunoassay, while also underscoring the clinical value of faster answers in horses at risk of laminitis. Because PPID diagnosis and dose titration often rely on endocrine testing, easier access to same-visit ACTH and insulin results could support earlier detection, faster treatment decisions, and closer monitoring in the field or clinic. (equimanagement.com)

What to watch: Watch for details on how broadly the reimbursement program rolls out, how many equine practices adopt it, and whether the partnership expands beyond ACTH and insulin into a broader endocrine testing pathway. (pharmiweb.com)